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Background: Based on the pharmacological potency and structural features of succinimides, this study was
designed to synthesize new ketoesters derivatives of succinimides. Furthermore, the synthesized compounds were
evaluated for their possible anticholinesterase and antioxidant potentials. The compounds were synthesized by
organocatalytic Michael additions of α-ketoesters to N-aryl maleimides. Acetyl and butyrylcholinesterase inhibitory
activities were determined using Ellman’s spectrophotometric assay. The antioxidant activity was performed with
DPPH and ABTS free radicals scavenging assay.
Results: The Michael additions of α-ketoesters to maleimides was promoted by 8-hydroxyquinoline. The organocatalyst
(8-hydroxyquinoline, 20 mol %) produced the compounds in relatively shorter time (20–24 h) and with
excellent isolated yields (84-98 %). The synthesized compounds (1–4) showed outstanding acetylcholinesterase (AChE)
and butyrylcholinesterase (BChE) inhibitory potentials, i.e., 98.75 and 90.00 % respectively for compound 2, with IC50
< 0.1 μg/mL. Additionally, compounds 1–4 revealed moderate antioxidant activity at different concentrations. In DPPH free
radical scavenging assay, compound 1 showed dominant result with 72.41 ± 0.45, 52.49 ± 0.78 and 35.60 ± 0.75 % inhibition
at concentrations of 1000, 500 and 250 μg/mL respectively, IC50 value of 440 μg/mL. However, the free radical scavenging
was better when used ABTS free radicals. In ABTS free radicals scavenging assay compound 1 exhibited 88.51 ± 0.62 %
inhibition at highest tested concentration i.e., 1000 μg/mL.
Conclusions: Herein, we have synthesized four ketoesters derivatives of succinimides in a single step reaction and high
yields. As a highlight, we have showed a first report on the anticholinesterase and antioxidant potentials of succinimides. All
the compounds showed overwhelming enzyme inhibitions and moderate antioxidant potentials.
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Alzheimer’s disease (AD), a chronic neurodegenerative dis-
order is the most common dementia effecting a greater
number of elder population worldwide [1]. Several biochem-
ical pathways are known for the management of AD but the
most important one is to inhibit a vital neurotransmitter re-
sponsible for signal transfer and cognitive functions [2]. In-
hibition of acetylcholine (ACh), the neurotransmitter, can
restore the level of ACh in the synaptic region and thus re-
instate deficient cholinergic neurotransmission [3]. In synap-
tic region, the acetylcholine hydrolyzes giving choline and
acetyl group with the help of biocatalyst acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE) [4]. The inhibi-
tions of AChE and BChE is the key target in the manage-
ment of AD [5]. Several natural and synthetic cholinesterase
inhibitors like galanthamine, donepezil, rivastigmine and tac-
rine (Fig. 1a) are reported but their use is limited due to se-
vere side effects and low efficiency [6]. Therefore, a main
goal of the current researchers is the development of novel,
safe, effective and economical drug candidates in the man-





























Fig. 1 a Natural and synthetic cholinesterase inhibitors; (b) Commonly em
its derivativesIn the last decade, it has been reported that AD is associ-
ated with inflammatory process in which reactive oxygen
species (ROS) are produced in the body [7]. The ROS are
able to damage biomolecules like enzymes, lipids, proteins,
DNA and RNA leading to inflammation [8]. To cope with
the situation, human body has the ability to follow several
defense mechanisms including enzymatic and non-
enzymatic antioxidant pathways [9]. However, this is practic-
ally impossible for the human body to scavenge all ROS and
attenuate inflammation processes [10]. Eventually, the excess
of ROS leads to the progression of chronic diseases like car-
diovascular diseases, cancer, diabetes, nephritis, rheumatism
and aging [11]. Therefore natural and synthetic antioxidants
are used employed in the management of neurological dis-
orders like AD [12]. The natural antioxidants are being
common in herbs, fruits and vegetables [13, 14]. Synthetic
antioxidants (Fig. 1b) are gallic acid esters, butylated hydroxy
toluene (BHT), tertiary butylated hydroquinone and butyl-
ated hydroxy anisole (BHA) [15]. Both natural and synthetic
antioxidants are associated with certain limitations like geo-
















ployed synthetic antioxidants; (c) General structures of succinimide and
Table 1 Synthesized ketoester derivatives of succinimides
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oxidants [18]. Therefore, a constant research is needed in
the field to find out safe and cost effective antioxidants.
Succinimides, a known class of anticonvulsant drugs
have been reported to posses several other pharmaco-
logical potentials [19]. The basic nuclei of succinimide is
“pyrrolidine-2,5-dione”, i.e. a five member ring with a ni-
trogen atom and two carbonyl groups as shown in
Fig. 1c. However, the basic skeleton can be modified to
C or N-substituted succinimides with different alkyl or
aryl groups which can lead to potential drug molecules
[20–23]. The commonly employed natural and synthetic
drugs in the treatment of AD possess nitrogen atom,
aromatic ring and/or carbonyl group in common in their
structure. Similarly, the compounds used in the scaven-
ging of free radicals must possess electron rich groups
like hydroxyl or conjugation in their structure as shown
in Fig. 1 (a & b).4 23 84
[a] Time of reaction completion; [b] Isolated yield after
column chromatographyResults and discussion
Synthesis of compounds (1–4)
Herein, we have synthesized four new ketoester deriva-
tives of succinimides (1–4) by organocatalytic Michael
additions of α-ketoesters to N-phenyl and N-benzyl mal-
eimides. A number of available nitrogenous compounds
were screened as achiral organocatalysts for the catalysis
of these reactions. Among them creatinine and 8-
hydroxyquinoline promote the reactions in relatively
shorter time with even low mol % loading. All the com-
pounds were synthesized in a reasonable reaction time
(less than 24 h) and with high isolated yields (84–98 %)
as shown in Table 1.Acetylcholinesterase inhibition assay
The purified products were evaluated for anticholines-
terase potentials (AChE & BChE) using Ellman’s assay as
shown in Tables 2 and 3 respectively.
The compounds (1–4) exhibited outstanding acetyl-
cholinesterase inhibitions (AChEI) potentials at three tested
concentrations (1000, 500 and 250 μg/mL) as shown in
Table 2. The highest observed acetylcholinesterase
inhibition was with compound 2 at concentration of
1000 μg/mL exhibiting 98.75 ± 0.25 % activity, IC50 < 0.1
μg/mL. Decreasing the concentration of 2 to 500 μg/mL
and then to 250μg/mL dropped the percent inhibitions to
91.75 ± 0.04 and 91.00 ± 0.52 % respectively. Similarly, at the
highest tested concentration (1000 μg/mL) compounds 1, 3
and 4 revealed 98.00 ± 0.70, 98.50 ± 0.09 and 97.25 ± 0.07 %
inhibitions respectively with IC50 of <0.1 μg/mL. Our com-
pounds were comparatively potent to the standard drug
galanthamine which reveal 94.22 ± 0.01, 92.28 ± 0.43 and
85.35 ± 0.83 % AChE inhibition at 1000, 500 and 250 μg/mL
concentrations respectively with IC50 < 0.1 μg/mL.Butyrylcholinesterase inhibition assay
The butyrylcholinesterase inhibitions (BChEI) of com-
pounds 1–4 are summarized in Table 3. In BChEI, com-
pound 2 proven to be most potent with IC50 value of
<0.1 μg/mL inhibiting 90.00 ± 0.10, 86.75 ± 0.22 and 84.25 ±
0.12 % BChE at concentrations of 1000, 500 and 250 μg/mL
respectively. The percent BChEI potentials of the remaining
three compounds were in an order of 4 > 3 > 1 with IC50
values of 2, 7 and 42 μg/mL respectively as shown in Table 3.
In comparison to galanthamine (positive control) all of our
four compounds (1–4) reached to a similar level of AChE
and BChE inhibitions.
DPPH free radicals scavenging assay
Antioxidant activity for the synthesized compounds were
evaluated using 1,1-diphenyl 2-picrylhydrazyl (DPPH)
and 2,2-azinobis[3-ethylbenzthiazoine]-6-sulfonic acid
(ABTS) as free radical sources. In DPPH free radicals
scavenging assay (Table 4), compound 1 showed a better
activity (72.41 ± 0.45 %) followed by 2, 3 and 4 with
Table 2 Acetylcholinesterase inhibition of compounds 1-4
Compounds Concentration Percent AChEI IC50
(μg/mL) (mean ± SEM) (μg/mL)
1 1000 98.00 ± 0.70ns <0.1
500 94.25 ± 0.05 ns
250 93.25 ± 0.25 ns
2 1000 98.75 ± 0.25 ns <0.1
500 91.75 ± 0.04 ns
250 91.00 ± 0.52 ns
3 1000 98.50 ± 0.09 ns <0.1
500 96.00 ± 0.80 ns
250 95.25 ± 0.20 ns
4 1000 97.25 ± 0.07 ns <0.1
500 96.00 ± 0.55 ns
250 93.25 ± 0.15 ns
Galanthamin 1000 94.22 ± 1.01 <0.1
e 500 92.28 ± 0.43
250 85.35 ± 0.83
Data is represented as mean ± SEM, n = 3
Two-way ANOVA followed by Bonferroni test was applied for significant
difference between standard drugs and test samples at 95 % confidence
interval. Values significantly not different in comparison to standard drug
Table 3 Butyrylcholinesterase inhibition of compounds 1-4
Compounds Concentration Percent AChEI IC50
(μg/mL) (mean ± SEM) (μg/mL)
1 1000 90.25 ± 0.02 ns 42
500 82.50 ± 0.18 ns
250 72.50 ± 0.02 ns
2 1000 90.00 ± 0.10 ns <0.1
500 86.75 ± 0.22 ns
250 84.25 ± 0.12 ns
3 1000 89.25 ± 0.50 ns 7
500 89.00 ± 0.30 ns
250 78.25 ± 0.04 ns
4 1000 98.50 ± 0.18 ns 2
500 88.50 ± 0.50 ns
250 87.50 ± 0.04 ns
Galanthamin 1000 94.50 ± 0.71 53
e 500 85.47 ± 0.59
250 71.72 ± 0.51
Data is represented as mean ± SEM, n = 3
Two-way ANOVA followed by Bonferroni test was applied for significant
difference between standard drugs and test samples at 95 % confidence
interval. Values significantly not different in comparison to standard drug
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scavenging respectively at highest tested concentration.
At the same tested concentration (1000 μg/mL), positive
control ascorbic acid reached to 93.56 ± 0.37 % free radi-
cals scavenging with IC50 20 μg/mL.
ABTS free radicals scavenging assay
The free radicals scavenging activity was slightly better
when using ABTS free radicals (Table 5). The potency of
compounds in ABTS free radicals scavenging activity was
in an order of 3 > 1 > 2 > 4 with IC50 values of 73, 90, 141
and 173 μg/mL respectively. Ascorbic acid scavenge 91.62
± 0.62, 87.23 ± 0.47 and 84.66 ± 0.88 % ABTS free radicals
at concentrations of 1000, 500 and 250 μg/mL respectively
with IC50 < 0.1 μg/mL.
Organocatalysis is an emerging field in practice over
the past decade [24]. Over this time different organoca-
talysts have been explored for various organic reactions
[25]. Michael addition is one of the important reactions
targeted by several researchers for testing potent organo-
catalysts [26]. In Michael addition reactions, maleimide
is an emerging acceptor substrate. The first report on
Michael addition of ketoesters to maleimides is pub-
lished in 2006 and since then such type of products are
uncommon in literature [27].
Medicinally, succinimides are vital drug candidates
and building blocks for natural products like δ-lactams
[28]. Various methods are available for the synthesis of
succinimides, but due to the emerging trend of organo-
catalytic reactions, Michael additions is a currently
employing method [29]. Asymmetric Michael additions
of aldehydes [20], ketones [21], cyanoacetates [22] and
ketoesters [23] derivatives have been reported. However,
most of the synthesized succinimides are unexplored
biologically and pharmacologically. To the best of our
literature search, ketoesters derivatives of succinimides
are not reported for anticholinesterase and antioxidant
potentials. Based on the gapes in the published literature
and the structural features of the available anticholines-
terase and antioxidant drugs (Fig. 1) this study was
designed to evaluate the ketoester derivatives of succini-
mides for anticholinesterase and antioxidant potentials.
As obvious from Fig. 1a that the commonly employed
cholinesterase inhibitors possess nitrogen atom, aromatic
ring and/or carbonyl group in their structure. In deter-
mining the acetyl and butyrylcholinesterase inhibitions
potentials our compounds reached to an excel level of
activity. A possible reason for this overwhelming cholin-
esterase inhibition might be the structural features similar-
ities with the commonly employed drugs as shown in
Fig. 1 (a & c). However, the commonly employed antioxi-
dants possess electron rich groups like hydroxyl and an
aromatic ring, as shown in Fig. 1b. All of our compounds
(1–4) contain aromatic ring in their main structures but
Table 4 DPPH free radicals scavenging assay of compounds 1-4
Compounds Conc. (μg/mL) Percent inhibition (mean ± SEM) IC50 (μg/mL)
1 1000 72.41 ± 0.45*** 440
500 52.49 ± 0.78***
250 35.60 ± 0.75***
2 1000 70.32 ± 0.61*** 460
500 52.48 ± 0.56***
250 33.61 ± 0.66***
3 1000 60.40 ± 0.49*** 535
500 54.64 ± 0.70***
250 30.59 ± 0.67***
4 1000 45.80 ± 0.61*** >1000
500 24.75 ± 0.64***
250 20.34 ± 0.58***
Ascorbic 1000 93.56 ± 0.37 20
acid 500 81.71 ± 0.54
250 78.61 ± 0.23
Data is represented as mean ± SEM, n = 3
Two-way ANOVA followed by Bonferroni test was applied for significant difference between standard drugs and test samples at 95 % confidence interval. Values
significantly different as compare to positive control, ***P <0.001
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ately resulted in moderate to poor free radicals scavenging.
Moreover, all of our four compounds have almost similar
structural units with very minor changes therefore they
exhibited almost a similar level of individual activities like

















Data is represented as mean ± SEM, n = 3
Two-way ANOVA followed by Bonferroni test was applied for significant difference
significantly different as compare to positive control, **P < 0.01 and ***P < 0.001Experimental
General information and instrumentation
All the chemical reactions were set up in 2.0 mL reaction
vial with cap. Liquid reagents were transferred with syrin-
ges. TLC analysis was performed for routine monitoring
of all the reactions. The TLC plates were precoated ofPercent inhibition (mean ± SEM) IC50 (μg/mL)
88.51 ± 0.62** 90
77.45 ± 0.54***
65.00 ± 0.57***
86.49 ± 0.49*** 141
72.45 ± 0.65***
59.66 ± 0.66***
80.41 ± 0.73*** 73
71.25 ± 0.48***
64.67 ± 0.89***
73.59 ± 0.43*** 173
67.33 ± 0.77***
54.00 ± 1.15***
91.62 ± 0.62 <0.1
87.23 ± 0.47
84.66 ± 0.88
between standard drugs and test samples at 95 % confidence interval. Values
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stain. All column chromatography were performed with
analytical grade silica gel (0.040-0.063 mm). n-Hexane and
ethyl acetate were used for column chromatography.
NMR spectra were recorded on JEOL ECX 400 spectrom-
eter, operating at 400 MHz for 1H and 100 MHz for 13C.
Chemical shifts (δ) were reported in parts per million (ppm)
downfield from tetramethylsilane (TMS= 0). Multiplicities
are abbreviated as: (s = singlet, d = doublet, t = triplet, q =
quartet, br = broad, m=multiplet). Coupling constants are
expressed in Hz. FT-IR spectra were obtained on Nicolet
Avatar 370 thermonicolet spectrometer. MS data was
measured on a Bruker Daltonics HCT Ultra. HRMS were
recorded on a Brukar micrOTOF instrument with an
ionization potential of 70 eV with ESI positive mode.
Ethyl 2-oxo-1-(2,5-dioxo-1-phenylpyrrolidin-3-
yl)cyclopentanecarboxylate (1)
Ethyl 2-oxocyclopentanecarboylate (2 mmol, 296.40 μl) in
combination with 8-hydroxyquinoline (20 mol %, 29.03 mg)
and potassium hydroxide (20 mol %, 11.20 mg) was added
to a small vial containing 1.0 mL of DCM. After stirring for
2 min added N-phenylmaleimide (1 mmol, 173 mg). The re-
action was stirred at room temperature and the progress of
reaction was monitored by TLC. The reaction got com-
pleted in 20 h. The reaction was stopped and diluted with
H2O (15 mL) and extracted with dichloromethane (3 ×
15 mL). All the organic layers were combined and dried
with anhydrous sodium sulfate (Na2SO4), filtered, and con-
centrated at reduced pressure using rotary evaporator. The
crude reaction mixture was purified by column chromatog-
raphy. The isolated yield of the pure product was calculated
after complete drying which was 95 % (312 mg).
1H NMR (400 MHz, CDCl3) (ppm): 1.16-1.20 (m, 3H),
1.71-2.22 (m, 2H), 2.35-2.40 (m, 3H), 2.40-2.70 (m, 2H),
2.94 (dd, J = 9.5, 18.3 Hz, 1H), 3.02-3.07 (m, 1H), 4.02-4.20
(m, 2H), 7.14-7.22 (m, 2H), 7.26-7.38 (m, 3H); (1H NMR
provided in additional file 1) 13C NMR (100 MHz, CDCl3)
(ppm): 12.97, 13.14, 18.65, 19.91, 26.37, 31.56, 31.61,
36.95, 37.01, 53.76, 59.96, 60.28, 61.15, 125.54, 127.60,
128.10, 130.77, 130.96, 168.44, 169.17, 173.57, 174.00,
175.49, 211.47, 211.89, 213.00; (13C NMR provided in
Additional file 1) FT-IR (KBr) vmax: 3435, 3021, 1745,
1720, 1658, 1646, 1283, 1108, 1035 cm1; MS (EI), m/z
(relative intensity): 352 [M+Na]+ (100 %); HRMS (ESI-
TOF): Calculated for C18H19NO5 [M+Na]
+ 352.1161;
found: 352.1149; Rf = 0.44 (EtOAc/n-Hex 1:5).
Ethyl 1-(1-benzyl-2,5-dioxopyrrolidin-3-yl)-2-
oxocyclopentanecarboxylate (2) [27]
Added ethyl 2-oxocyclopentanecarboxylate (2 mmol,
295.80 μl) to dichloromethane (1.0 mL) followed by 8-
hydroxyquinoline (20 mol %, 29.03 mg) and potassium
hydroxide (20 mol %, 11.20 mg) and stir for 2 min. Thenadded N-benzylmaleimide (1 mmol, 187.19 mg) to the
reaction and continue stirring at room temperature.
The progress of the reaction was monitored by TLC.
Full conversion of the starting material was observed in
24 h. The reaction was stopped and diluted with H2O
(15 mL) and extracted with dichloromethane (3 ×
15 mL). All the organic layers were combined and dried
with anhydrous sodium sulfate (Na2SO4), filtered, and
concentrated at reduced pressure using rotary evapor-
ator. The crude reaction mixture was purified by col-
umn chromatography. The isolated yield of the pure
product was calculated after complete drying which was
91 % (312 mg).
1H NMR (400 MHz, CDCl3) (ppm): 1.20 (t, J = 7.1 Hz,
3H), 1.73-1.84 (m, 1H), 1.93-2.14 (m, 2H), 2.19-2.25 (m,
2H), 2.30-2.63 (m, 2H), 2.76-2.87 (m, 1H), 3.07 (t, J = 9.0
Hz, 1H), 4.02-4.14 (m, 4H), 7.09-7.23 (m, 3H), 7.28-7.40
(m, 2H); (1H NMR provided in Additional file 1) 13C
NMR (100 MHz, CDCl3) (ppm): 9.33, 9.40, 14.66, 18.13,
18.18, 21.43, 26.91, 27.02, 37.67, 45.93, 53.58, 56.78,
58.16, 62.40, 60.08, 116.60, 120.42, 120.66, 128.14,
128.63, 137.12, 177.02, 184.58, 186.81, 217.81; Rf = 0.53




To a stirred reaction containing ethyl-2-oxocyclohexane-
carboxylate (2 mmol, 319.90 μl), creatinine (20 mol %,
22.60 mg) and potassium hydroxide (20 mol %,
11.20 mg) in DCM (1.0 mL) was added N-phenylmalei-
mide (1 mmol, 173.17 mg). The reaction was continued
at room temperature and progress was monitored by
using TLC. The reaction got completed in 22 h. The re-
action was stopped and diluted with H2O (15 mL) and
extracted with dichloromethane (3 × 15 mL). All the or-
ganic layers were combined and dried with anhydrous
sodium sulfate (Na2SO4), filtered, and concentrated at
reduced pressure using rotary evaporator. The crude re-
action mixture was purified by column chromatography.
The isolated yield of the pure product was calculated
after complete drying which was 98 % (336 mg).
1H NMR (400 MHz, CDCl3) (ppm): 0.85 (t, J = 7.5 Hz,
3H), 1.18-1.39 (m, 6H), 1.58-1.70 (m, 2H), 2.40-2.47 (m,
1H), 2.60-2.82 (m, 2H), 4.11-4.19 (m, 2H), 7.19-7.42 (m,
3H), 7.46 (dd, J = 3.4, 5.7, 1H), 7.64 (dd, J = 3.3, 5.8, 1H);
(1H NMR provided in Additional file 1) 13C NMR (100
MHz, CDCl3) (ppm): 12.93, 13.01, 13.21, 17.23, 18.87,
23.37, 36.88, 39.99, 41.13, 52.95, 59.24, 59.79, 60.14, 60.45,
61.45, 126.15, 126.24, 127.08, 128.64, 130.04, 167.98,
169.26, 173.21, 174.82, 212.05, 213.70; (13C NMR provided
in additional file 1) FT-IR (KBr) vmax: 3422, 2947, 1754,
1655, 1628, 1608, 1442, 1403, 1246, 1137, 927 cm1; MS
(EI), m/z (relative intensity): 366 [M+Na]+ (100 %);
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+
366.1317; found: 366.1312; Rf = 0.55 (EtOAc/n-Hex 1:5).
1Ethyl 1-(1-benzyl-2,5-dioxopyrrolidin-3-yl)-2-
oxocyclohexanecarboxylate (4)
The reaction was started by addition of ethyl 2-oxocyclohex-
anecarboxylate (2 mmol, 319.90 μl) to DCM (1.0 mL) con-
taining creatinine (20 mol %, 22.60 mg) and potassium
hydroxide (20 mol %, 11.20 mg) in a vial. After 2 min of stir-
ring, N-benzylmaleimide (187.19 mg) was continued the re-
action at room temperature. TLC was used to monitor the
progress of reaction. The reaction completed in 23 h. The
reaction was stopped and diluted with H2O (15 mL) and ex-
tracted with dichloromethane (3 × 15 mL). All the organic
layers were combined and dried with anhydrous sodium sul-
fate (Na2SO4), filtered, and concentrated at reduced pressure
using rotary evaporator. The crude reaction mixture was
purified by column chromatography. The isolated yield of
the pure product was calculated after complete drying which
was 84 % (300 mg).
1H NMR (400 MHz, CDCl3) (ppm): 0.85 (t, J = 7.5 Hz,
3H), 1.18-1.37 (m, 4H), 1.57-1.68 (m, 2H), 1.72-1.78 (m,
1H), 2.40-2.47 (m, 1H), 2.57 (dd, J = 9.2, 18.0 Hz, 1H),
2.65-2.73 (m, 1H), 3.12 (dd, J = 6.0, 9.2 Hz, 1H), 4.10-4.20
(m, 2H), 4.52-4.67 (m, 2H), 7.18-7.28 (m, 3H), 7.30-7.33
(m, 2H); (1H NMR provided in additional file 1) 13C NMR
(100 MHz, CDCl3) (ppm): 9.93, 13.04, 13.11, 20.59, 21.95,
25.59, 2933, 31.35, 31.90, 37.70, 39.71, 41.38, 42.76, 61.17,
61.61, 62.07, 67.13, 126.70, 127.59, 127.62, 127.78, 129.86,
131.43, 134.73, 166.73, 174.23, 175.82, 176.34, 205.59,
205.75; (13C NMR provided in Additional file 1) FT-IR
(KBr) vmax: 3430, 2911, 1760, 1700, 1625, 1590, 1480,
1428, 1370, 1230, 1180, 1025, 915, 680 cm1; MS (EI), m/z
(relative intensity): 380 [M+Na]+ (100 %); HRMS (ESI-
TOF): Calculated for C20H23NO5 [M+Na]
+ 380.1474;
found: 380.1500; Rf = 0.63 (EtOAc/n-Hex 1:5).
Conclusions
In conclusion, we synthesize new ketoesters derivatives of
succinimides. All the compounds were synthesized in a
single step reaction and with high isolated yields. The
highlight of the work was the first report and overwhelm-
ing AChEI and BChEI potentials of compounds 1–4
which reflect their dominant role in AD. Moreover, the
compounds also scavenge DPPH and ABTS free radicals
to a moderate level which supplement their use for AD in
combination with anticholinesterase potentials. Further
synthesis and biological evaluation is in progress in our
laboratory.
Methods
Synthesis of compounds (1–4)
To a small reaction vial containing DCM (1 M) was added
α−ketoester (ethyl 2-oxocyclopentanecarboxylate or ethyl2-oxocyclohexanecarboxylate, 2 mmol). Then added orga-
nocatalyst (creatinine or 8-hydroxyquinoline, 20 mol %)
and potassium hydroxide (20 mol %) and start stirring.
After 2 min of stirring, added maleimide (N-phenyl or N-
benzylmaleimide, 1 mmol). The progress of reaction was
monitored by thin layer chromatography. At complete
conversion, the reaction mixture was diluted with water
(15 mL) and extracted with dichloromethane (3 × 15 mL).
All the organic layers were combined and dried with an-
hydrous sodium sulfate (Na2SO4), filtered and concen-
trated at reduced pressure using rotary evaporator. The
crude reaction mixture was then purified by column
chromatography.
Anticholinesterase assays
The acetylcholinesterase (AChE) from Electric eel and bu-
tyrylcholinesterase (BChE) from equine serum were used in
the determination of anticholinesterase assays of com-
pounds 1–4. The assay is based on the acetylcholinesterase
promoted hydrolysis of acetylthiocholine iodide and butyr-
ylthiocholine iodide by butyrylcholinesterase. The hydroly-
sis processes give 5-thio-2-nitrobenzoate anion followed by
complexation with DTNB (which give yellow color) and is
detected by the spectrophotometer [30].
Preparation of solutions
Compounds (each separately) were dissolved in phosphate
buffer (0.1 M) in concentrations ranging from 250–
1000 μg/mL. For the preparation of 0.1 M and 8.0 ± 0.1
PH phosphate buffer solution, K2HPO4 (17.4 g/l) and
KH2PO4 (13.6 g/l) were prepared and were mixed in 94 %
and 6 % ratio respectively. Finally, potassium hydroxide
was used to adjust pH. AChE (518 U/mg solid) and BChE
(7–16 U/mg) were diluted in freshly prepared buffer
pH 8.0 until final concentrations of 0.03 U/mL and 0.01
U/mL were obtained. Solutions of DTNB (0.0002273 M),
ATchI and BTchI (0.0005 M) were prepared in distilled
water and were kept in Eppendorf caps in the refrigerator.
Galanthamine (Positive control) was dissolved in metha-
nol and aforementioned dilutions were prepared [31].
Spectroscopic analysis
For each assay, an enzyme solution of 5 μl was added to
the cuvette followed by addition of compound (205 μl), and
finally DTNB reagent (5 μl). The solution mixture was
maintained at 30 °C for 15 min using water bath with sub-
sequent addition of substrate solution (5 μl). A double
beam spectrophotometer was used to measure the absorb-
ance at 412 nm. Negative control contained all components
except compounds, whereas positive control galanthamine
(10 μg/mL) was used in the assay as standard cholinesterase
inhibitor. The absorbances along with the reaction time
were taken for four minutes at 30 °C and were repeated in
triplicate. Finally, the enzyme activity and enzyme inhibition
Sadiq et al. Chemistry Central Journal  (2015) 9:31 Page 8 of 9by control and tested samples were calculated from the rate
of absorption with change in time (V =ΔAbs /Δt) as follow;
% enzyme inhibition = 100 - percent enzyme activity
% enzyme enzme activity ¼ 100  V
Vmax
Where Vmax is enzyme activity in the absence of inhibi-
tor drug.
DPPH free radical scavenging assay
The compounds’ free radical scavenging ability was evalu-
ated using 1,1-diphenyl, 2-picrylhydrazyl (DPPH) free rad-
icals [32]. Different dilutions (250, 500 and 1000 μg/mL)
of compounds (0.1 mL) were added to 0.004 % methanolic
solution of DPPH. After 30 min the absorbance was mea-
sured at 517 nm using UV spectrophotometer. Ascorbic
acid was used as positive control.





Where A0 is absorbance of control and A1 is the ab-
sorbance of the compound sample. Each experiment was
performed in triplicate and inhibition curves were con-
structed using the GraphPad prism program (Graph-
PAD, San Diego, California, USA) and median inhibitory
concentrations (IC50) values were determined.
ABTS free radical scavenging assay
ABTS (2, 2-azinobis [3-ethylbenzthiazoline]-6-sulfonic acid)
free radicals were also used to confirm the antioxidant activ-
ity of the synthesized compounds. The activity is based on
the capacity of antioxidants to scavenge ABTS+ radical cat-
ion causing a reduction in absorbance at 734 nm. ABTS
(7 mM) and K2S2O4 (2.45 mM) solutions were prepared
and mixed. The resultant mixture was maintained at room
temperature in dark for 12–16 h to get dark color solution
containing ABTS+ radical cations. At the time of activity,
ABTS+ radical cation solution was diluted with Phosphate
buffer (0.01 M) pH 7.4 to adjust an absorbance value of 0.70
at 734 nm. Radical scavenging capability of the compounds
was analyzed by mixing 300 μl of compound with 3.0 mL of
ABTS solution in cuvette. The reduction in absorbance was
measured spectrophotometrically after one minute of mix-
ing the solutions and continued for six min. Ascorbic acid
was used as a positive control. The assay was repeated three
times and percent inhibition was calculated with formula;
% scavenging effect ¼ Control absorbance‐Sample absorbance
Control absorbance
 100
The antioxidant effect was expressed in terms of per-
cent inhibition and as EC50 (compounds concentration
required for 50 % reduction of ABTS radicals).Estimation of IC50 values
Concentrations of the compounds that inhibited substrate
hydrolysis (AChE and BChE) by 50 % (IC50). Radical scav-
enging ability was calculated by a linear regression analysis
among the inhibition percentages against the compounds
concentrations via the Excel program.
Statistical analysis
Data is represented as mean ± SEM, n = 3. Two-way
ANOVA followed by Bonferroni test was applied for sig-
nificant difference between standard drugs and test sam-
ples at 95 % confidence interval. Values were considered
significantly different with * P < 0.05, ** P < 0.01 and P <
0.001. ns: Test compounds non significantly different in
comparison to standard drug P > 0.05.
Additional file
Additional file 1: The 1H & 13C NMRs of the synthesized
compounds are provided.
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